Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Joint ASH and AABB educational session.

Lawrence T Goodnough1, Patricia E Hewitt, Christopher C Silliman

  • 1Transfusion Medicine Service, Washington University Medical School and Barnes-Jewish Hospital, St. Louis, MO, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomic analyses of longitudinal plasma samples identify thromboinflammation endotypes and trajectories in patients with trauma.

Science translational medicine·2026
Same author

Cytoprotective 3K3A-activated protein C and plasma: A comparison of therapeutics for the endotheliopathy of trauma.

The journal of trauma and acute care surgery·2024
Same author

Platelet releasates mitigate the endotheliopathy of trauma.

The journal of trauma and acute care surgery·2024
Same author

Trauma patients with type O blood exhibit unique multiomics signature with decreased lectin pathway of complement levels.

The journal of trauma and acute care surgery·2024
Same author

Smoking primes the metabolomic response in trauma.

The journal of trauma and acute care surgery·2024
Same author

Endothelial Cell Calcium Influx Mediates Trauma-induced Endothelial Permeability.

Annals of surgery·2023
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Transfusion medicine specialists focus on bedside care, addressing new variant Creutzfeldt-Jakob disease (nvCJD) transmission risks and transfusion-related acute lung injury (TRALI). This chapter also explores recombinant factor VIIa (rFVIIa) use in clinical settings.

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Infectious Disease Epidemiology

Background:

  • The role of transfusion medicine specialists has shifted towards direct patient care at the bedside.
  • Blood safety and conservation are critical concerns in modern transfusion practices.
  • Emerging infectious diseases and transfusion reactions pose significant challenges.

Purpose of the Study:

  • To review current knowledge and clinical issues in transfusion medicine.
  • To discuss the risks of new variant Creutzfeldt-Jakob disease (nvCJD) transmission via blood.
  • To explore the pathophysiology, prevention, and treatment of transfusion-related acute lung injury (TRALI).
  • To present an approach for the clinical use of recombinant factor VIIa (rFVIIa).

Main Methods:

Related Experiment Videos

  • Review of epidemiologic and clinical evidence for nvCJD in transfusion medicine.
  • Summary of recent research on TRALI etiologies, prevention, and treatment.
  • Presentation of institutional policies for off-label use of rFVIIa.

Main Results:

  • Evidence suggests potential transmission of nvCJD and prion proteins through blood transfusion.
  • TRALI is a leading cause of transfusion-related mortality, with proposed dual etiologies.
  • rFVIIa shows potential as a hemostatic agent, but clinical trial data is limited.

Conclusions:

  • Transfusion medicine must adapt to emerging threats like nvCJD and TRALI.
  • Understanding TRALI's mechanisms is crucial for prevention and management.
  • Clinical application of rFVIIa requires careful consideration and ongoing data collection.